Adamas Pharmaceuticals Q3 EPS $(0.99) Misses $(0.89) Estimate, Sales $13.933M Miss $14.07M Estimate

Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.89) by 11.24 percent. This is a 18.85 percent increase over losses of $(1.22) per

Benzinga · 11/07/2019 21:35

Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.89) by 11.24 percent. This is a 18.85 percent increase over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $13.933 million which missed the analyst consensus estimate of $14.07 million by 0.97 percent. This is a 31.28 percent increase over sales of $10.613 million the same period last year.